Key terms
About EBS
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EBS news
Mar 28
8:22am ET
Emergent BioSolutions continues to broaden access of NARCAN nasal spray
Mar 25
8:38am ET
Emergent BioSolutions receives NAI status for Baltimore Bayview facility
Mar 07
10:14am ET
Emergent BioSolutions upgraded to Buy at Benchmark after ‘upbeat’ Q4 report
Mar 07
10:11am ET
Emergent BioSolutions upgraded to Buy from Hold at Benchmark
Mar 06
5:07pm ET
Emergent BioSolutions sees Q1 revenue $200M-$250M, consensus $185.4M
Mar 06
5:06pm ET
Emergent BioSolutions sees FY24 revenue $900M-$1.1B, consensus $1.18B
Mar 06
5:04pm ET
Emergent BioSolutions reports Q4 EPS (77c), consensus (19c)
Mar 06
4:34pm ET
Emergent BioSolutions Secures Flexible Credit Terms and Guarantor
Mar 06
2:04pm ET
Emergent BioSolutions options imply 36.4% move in share price post-earnings
Mar 04
2:34pm ET
Emergent BioSolutions options imply 25.1% move in share price post-earnings
Feb 23
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 21
7:46am ET
Emergent Biosolutions Welcomes Joseph Papa as New CEO
Feb 21
7:15am ET
Emergent BioSolutions appoints Papa as new president, CEO
Jan 17
11:00am ET
Emergent extending shelf-life of newly manufactured NARCAN, FDA says
Jan 11
10:20am ET
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Emergent Biosolutions (EBS)
Jan 11
8:03am ET
Emergent BioSolutions awarded procurement contract valued up to $235.8M
Jan 08
10:15pm ET
Lightning Could Strike Twice for Biotech Penny Stock Chimerix (NASDAQ:CMRX)
No recent press releases are available for EBS
EBS Financials
Key terms
Ad Feedback
EBS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EBS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range